N-alpha-acetyltransferase 11, NatA catalytic subunitGenealiases: ARD1B · ARD2 · hARD2
Q-omics provides the consensus-scored NAA11 profile across patient tissues and cancer cell-line models. NAA11 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, NAA11 is differentially expressed in 6, with the highest sampling consensus in BRCA. Additionally, NAA11 RNA expression shows 10,765 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, BRCA, and TGCT as cancer lineages where NAA11 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NAA11 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NAA11 survival associations across molecular data types. NAA11 RNA expression shows survival associations in the most cancer types (15), followed by mutation status (4) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NAA11 RNA expression–survival associations across cancer types. High NAA11 expression shows unfavorable associations in KIRC, KICH, UVM, COAD, THCA and ACC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .006). Together, the overview and detailed table identify KIRC as the clearest survival context for NAA11 RNA expression.
This table summarizes NAA11 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6, while mass-spec protein shows differences in 3. The strongest signals are observed in BRCA for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for NAA11. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NAA11 shows lower tumor expression in BRCA and higher tumor expression in LIHC, UCEC, THCA, LUAD and LUSC. The BRCA box plot shows higher NAA11 RNA expression in normal versus tumor tissue (log2 FC = −0.062, t-test p < 0.001).
This table shows molecular features associated with NAA11 in patient tissues and cancer cell lines. In patient samples, NAA11 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, NAA11 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
